TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3542470
Drug: Ceftriaxone (Rocephin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (Rocephin 2 g single dose)
Study: 30241227
Drug: Adjuvant carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant carboplatin and paclitaxel chemotherapy followed by radiotherapy
Study: 27006549
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg intravenously
Study: 27006549
Drug: Butorphanol 1
Normalized name: butorphanol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 1 mg intravenously
Study: 27006549
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 3 ml intravenously (placebo)
Study: 17985084
Drug: Preemptive warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive warfarin dose reduction (10‐20%)
Study: 17985084
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change in warfarin dosing (Control)
Study: 17985084
Drug: Preemptive warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive warfarin dose reduction (10‐20%) with TMP‐SMX
Study: 17985084
Drug: Preemptive warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive warfarin dose reduction (10‐20%) with levofloxacin
Study: 12679925
Drug: Routine drugs
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drugs (VitC, aspartic acid)
Study: 1400985
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza B reassortant virus vaccine (doses ranging from 10(3.2) to 10(6.2) TCID50)
Study: 1400985
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza B reassortant virus vaccine
Study: 29133606
Drug: Roux‐en‐Y gastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux‐en‐Y gastric bypass plus medical therapy
Study: 17135986
Drug: COMB (fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMB (fluoxetine + cognitive-behavioral therapy)
Study: 17135986
Drug: FLX (fluoxetine)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLX (fluoxetine)
Study: 17135986
Drug: CBT (cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT (cognitive-behavioral therapy)
Study: 10733540
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg twice per day) for 1 week
Study: 29076666
Drug: Topical Turpentine
Normalized name: turpentine
DrugBank: Turpentine (DB11120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Turpentine Oil
Study: 19349130
Drug: Carbosylane (activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbosylane (activated charcoal-simethicone combination)
Study: 9412397
Drug: Amoxycillin/potassium clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/potassium clavulanate (amoxyclav) 1.2 g IV every 8 hours for 2 days, then 625 mg orally thrice a day for 5 days
Study: 9412397
Drug: Cefotaxime 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1.0 g IM every 8 hours for 7 days
Study: 2418292
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg, intravenously)
Study: 25127927
Drug: Alcohol session
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol session (.82 g/kg)
Study: 23458986
Drug: Sugared PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugared PEG solution
Study: 23458986
Drug: Standard PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PEG solution
Study: 14564460
Drug: Synthetic lycopene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic lycopene (Lycovit 10%, 15 mg/day for 28 days)
Study: 14564460
Drug: Tomato-based lycopene
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato-based lycopene (Lyc-O-Mato, 15 mg/day for 28 days)
Study: 14564460
Drug: Placebo (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (without lycopene, 15 mg/day for 28 days)
Study: 10670117
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg tramadol (Group T)
Study: 8965951
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of lymphocytes from the original bone marrow donor
Study: 1365472
Drug: naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (500 mg b.d.)
Study: 1365472
Drug: diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (50 mg t.i.d.)
Study: 6883914
Drug: Chloroquine 2
Normalized name: chloroquine 24.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 2 mg/kg
Study: 6883914
Drug: Chloroquine 3
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 3 mg/kg
Study: 6883914
Drug: Chloroquine 5
Normalized name: chloroquine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 5 mg/kg
Study: 6883914
Drug: Chloroquine 10
Normalized name: chloroquine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 10 mg/kg
Study: 6883914
Drug: Chloroquine 15
Normalized name: chloroquine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 15 mg/kg
Study: 24290286
Drug: Voriconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (200 mg twice daily for 3 months)
Study: 22180344
Drug: MAID/RT regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAID/RT regimen (mesna, Adriamycin, ifosfamide, dacarbazine) with 3 cycles of preoperative chemotherapy and 44 Gy of RT followed by surgery and 3 cycles of postoperative MAID, with additional 16 Gy of RT for positive surgical margins.
Study: 17962233
Drug: General population
Approvals — FDA: no, EMA: no, PMDA: no
Description: General population characteristics (e.g., gender, BMI, smoking status)
Study: 10516349
Drug: L-carnitine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (10 mg/kg intravenously at the end of each hemodialysis session for 4 months)
Study: 10516349
Drug: L-carnitine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (in vitro incubation)
Study: 1804788
Drug: Regimen I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I: daily single-dose treatment with 200 mg of ofloxacin
Study: 1804788
Drug: Regimen II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II: every two week multidose treatment with 3 x 200 mg/day of ofloxacin
Study: 7068895
Drug: Negative practice
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative practice treatment
Study: 31090440
Drug: Bilateral posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral posterior quadratus lumborum blockade with 25-30 mL of 0.25% levobupivacaine
Study: 29423410
Drug: Ulinastatin (UTI)
Normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (UTI) administered intravenously during surgery
Study: 26372470
Drug: Medication monitor
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication monitor
Study: 26372470
Drug: Combined (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (medication monitor + text messaging)
Study: 24217301
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g orally)
Study: 24217301
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C + E (2 g vitamin C with 600 mg vitamin E orally)
Study: 15168289
Drug: Conventional conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional conservative therapy
Study: 1592346
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) plus Ursodeoxycholic acid (600 mg/day)
Study: 2439007
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram intradermal HBV vaccine given to neonates with BCG, followed by two doses of 1.0 microgram intradermal HBV vaccine.
Study: 2439007
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 2 micrograms HBV vaccine intradermally after a 20 micrograms intramuscular dose or three doses of 2 micrograms intradermally.
Study: 2439007
Drug: 4 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 micrograms of HBV vaccine given intradermally to 20 young children with a multiple orifice head fired by a jet gun.
Study: 2439007
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 20 micrograms HBV intramuscularly followed by two 10 micrograms doses intramuscularly.
Study: 31786135
Drug: CPCB‐RPE1 implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPCB‐RPE1 implant (3.5×6.25 mm)
Study: 26595968
Drug: Multi-channel electrical
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-channel electrical stimulation and microcurrent therapy
Study: 23230124
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg zeranol
Study: 23230124
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg zeranol
Study: 23230124
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg zeranol
Study: 23230124
Drug: 36 mg
Normalized name: pyrantel 136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg zeranol
Study: 21907949
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with clopidogrel (300 mg loading dose before TAVI, followed by 75 mg daily for 3 months) plus aspirin (100 mg lifelong)
Study: 21907949
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (100 mg lifelong)
Study: 21907949
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin
Study: 12782826
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding (clear liquid diet on the first postoperative day, then advanced to a regular diet)
Study: 8818186
Drug: L-lactic acid
Normalized name: L-Lactic acid
DrugBank: L-Lactic acid (DB14475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lactic acid
Study: 8818186
Drug: D,L-lactic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L-lactic acid
Study: 1429406
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg qd)
Study: 20508468
Drug: G+AnE
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+AnE
Study: 20508468
Drug: G+AE
Normalized name: Gabapentin and Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+AE
Study: 18569019
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (G-CSF) 5 microg/kg, o.d. for 5 days after adjuvant chemotherapy
Study: 10795673
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (n = 12)
Study: 3885387
Drug: Noscapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noscapine (30 mg)
Study: 3885387
Drug: Dihydrocodeine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine (30 mg)
Study: 29438808
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg qd)
Study: 24401626
Drug: Cortical hormone
Normalized name: Adrenal cortical hormone-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortical hormone
Study: 20516435
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (paclitaxel-carboplatin) followed by surgery
Study: 20516435
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (paclitaxel-carboplatin) after surgery
Study: 18086944
Drug: Lactotripeptides (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactotripeptides (200 mL dairy drink with 14 mg lactotripeptides)
Study: 14522728
Drug: Beta-glucan-enriched barley
Normalized name: yeast, beta-D-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan-enriched barley (8.1-11.9 g beta-glucan/d)
Study: 14522728
Drug: Control (isoenergetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isoenergetic dose of 6.5-9.2 g glucose/d)
Study: 7795837
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g of calcium carbonate)
Study: 7795837
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (360 mg of magnesium diglycine)
Study: 2046334
Drug: Heroin hydrochloride
Normalized name: heroin hydrochloride
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin hydrochloride (3.0 mg)
Study: 2046334
Drug: Heroin hydrochloride
Normalized name: heroin hydrochloride
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin hydrochloride (6.0 mg)
Study: 2046334
Drug: Free morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free morphine
Study: 2046334
Drug: Total morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total morphine
Study: 2046334
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and codeine administration
Study: 7446455
Drug: Vitamin C,
Normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C, 800 mg four times daily for 2 days before surgery and 2 weeks after surgery
Study: 30821047
Drug: Ipragliflozin 25
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 25 mg/day
Study: 21317198
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin G (IM BPG)
Study: 17878421
Drug: Frequent nocturnal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Frequent nocturnal hemodialysis (6 times weekly)
Study: 17878421
Drug: Conventional hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional hemodialysis (3 times weekly)
Study: 11532463
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal E(2) plus acetate nomegestrolo (group A1)
Study: 11532463
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) continuously administered (group B1)
Study: 11532463
Drug: Short-term suspension
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term suspension of HRT (group A2)
Study: 11532463
Drug: Short-term suspension
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term suspension of HRT (group B2)
Study: 11532463
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (group C)
Study: 9754191
Drug: Diclofenac 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 0.1% ophthalmic solution
Study: 7653444
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (12 g/day of fish oil, approximately 8.5 g of n-3 fatty acids)
Study: 7653444
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil (12 g/day of rapeseed oil)
Study: 2765430
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg thrice daily for 3‐5 days in two cycles)
Study: 2765430
Drug: Danazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (100 mg twice daily for 60 days)
Study: 24641096
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) treatment followed by twice daily applications of timolol gel
Study: 24641096
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) treatment alone
Study: 2535870
Drug: Pyridoxine supplementation
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine supplementation (10 mg per day)
Study: 26489389
Drug: Dexamethasone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (two 4 mg tablets taken orally at least 1 hour before radiation treatment and daily for 4 days after)
Study: 26489389
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two placebo tablets taken orally at least 1 hour before radiation treatment and daily for 4 days after)
Study: 21555331
Drug: CRF(1) receptor
Normalized name: CRF
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRF(1) receptor antagonist R317573, 40 mg for 7 days
Study: 21555331
Drug: Lorazepam (LZP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (LZP), 2 mg as positive control on day 8
Study: 20109697
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin once daily
Study: 14501734
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg tamsulosin once daily
Study: 14501734
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 or 0.8 mg once daily) long-term
Study: 10936115
Drug: Metered-dose inhalers
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhalers (MDIs) with Nebulizer Chronologs (NCs) monitoring
Study: 9062840
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral lifestyle intervention (weight loss goals of 5 to 15 lb, 20 weekly group meetings)
Study: 3400411
Drug: Lorazepam 4
Normalized name: lorazepam 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 4 mg oral fast dissolving drug formulation (FDDF)
Study: 26425703
Drug: Trastuzumab 6
Normalized name: Trastuzumab 60 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab 6 mg/kg IV in 90 min (n = 46)
Study: 21144106
Drug: Konjac glucomannan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Konjac glucomannan (KGM) 4.5 g/d
Study: 9085304
Drug: Kapanol (24-hourly)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kapanol (24-hourly)
Study: 9085304
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin (12-hourly)
Study: 3327353
Drug: High-dose acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acetylsalicylic acid (ASA)
Study: 3327353
Drug: Dihydroergotamine-heparin (DHEH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine-heparin (DHEH)
Study: 27573564
Drug: Sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin (SorCDDP: sorafenib 400 mg bid; cisplatin 65 mg/m2, day 1, every 4-6 weeks)
Study: 23043164
Drug: Insulin analogs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin analogs with rHuPH20
Study: 23043164
Drug: Insulin analogs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin analogs without rHuPH20
Study: 20881606
Drug: felodipine-ER 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine-ER 5 mg/d
Study: 12828690
Drug: Purpura-level treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purpura-level treatment (0.5 J/cm2 greater than the purpura threshold)
Study: 12828690
Drug: Purpura-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purpura-free treatment (1.0 J/cm2 less than the purpura threshold)
Study: 12828690
Drug: Purpura-level treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purpura-level treatment
Study: 12828690
Drug: Purpura-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purpura-free treatment
Study: 12828690
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (purpura and purpura-free)
Study: 6376016
Drug: Guar mini‐tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar mini‐tablets (5 g t.i.d.)
Study: 25123988
Drug: Testosterone 2%
Normalized name: TESTOSTERONE 2% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 2% solution applied after deodorant/antiperspirant to shaved axillae
Study: 25123988
Drug: Testosterone 2%
Normalized name: TESTOSTERONE 2% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 2% solution applied to unshaved axillae
Study: 25123988
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including deodorant/antiperspirant and shaved/unshaved axillae)
Study: 22044402
Drug: PF-04457845 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04457845 (single dose)
Study: 22044402
Drug: PF-04457845 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04457845 (multiple dose)
Study: 22044402
Drug: PF-04457845 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04457845 (up to 40 mg single dose and 8 mg once daily for 14 days)
Study: 11952486
Drug: Fucidic acid
Normalized name: Fucidate
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucidic acid (1.0%) eye drops applied twice per day
Study: 2374773
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light (2,500 lux) for 2 hours daily
Study: 2374773
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light (50 lux) for 2 hours daily
Study: 115046
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (flupenthixol and fluphenazine)